Breast cancer brain metastases: Differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 942-948

  Niwinska A ^a   Murawska, M ^b   Pogoda, K ^a  

^a Departments of Breast Cancer and Reconstructive Surgery   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Brain metastasis; HER2 positive breast cancer; RPA RTOG prognostic class; Systemic treatment; Triplenegative breast cancer; Whole brain radiotherapy (WBRT)

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; GOSERELIN; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; HEALTH STATUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953346211     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp407     Document Type: Article

References (24)

1. Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008; 20: 676-684.
2. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
3. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751.
4. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
5. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
6. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-153.
7. Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45: 196-201.
8. Tham YL, Sexton K, Kramer R et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.
9. Nam BH, Kim SY, Han HS et al. Breast cancer subtypes and survival in patients with brain metastases. Cancer Res 2008; 10: R20.
10. Niwińska A, Tacikowska M, Pieńkowski T. Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol 2007; 46: 1027-1029.
11. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40: 379-382.
12. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.
13. Niwińska A, Rudnicka H, Krajewski R, Murawska M. Surgery and radiotherapy of brain metastases in breast cancer patients-an analysis of survival and prognostic factors. Nowotwory 2007; 57: 140-145.
14. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69: 972-980.
15. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599-1605.
16. Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006; 78: 255-260.
17. Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001; 24: 421-424.
18. Tosoni A, Franceschi E, Brandes AA. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 2008; 68: 212-221.
19. Pors H, von Eyben FE, Sorensen OS, Larsen M. Longterm remission of multiple brain metastases with tamoxifen. J Neurooncol 1991; 10: 173-177.
20. Madhup R, Kirti S, Bhatt ML et al. Letrozole for brain and scalp metastases from breast cancer-a case report. Breast 2006; 15: 440-442.
21. Church DN, Modgil R, Guglani S et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008; 31: 250-254.
22. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19: 1242-1248.
23. Park IH, Ro J, Lee KS et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009; 20: 56-62.
24. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993-1999.